Literature DB >> 30183478

MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma.

Fajun Qu1, Jianqing Ye1, Xiuwu Pan1, Junkai Wang2, Sishun Gan1, Chuanmin Chu1, Jian Chu3, Xiangmin Zhang3, Mei Liu1, Hua He4, Xingang Cui1,3.   

Abstract

Recent advances in immunotherapy are raising hope to treat clear cell renal cell carcinoma (ccRCC) with PD-L1 inhibitors, but only a small portion of patients are PD-L1 positive. The heterogeneous expression pattern of PD-L1 in patient population suggests that PD-L1 expression is under the control of diverse regulatory mechanisms. Although recent studies have identified numerous novel PD-L1 regulators, reports on microRNAs which modulate PD-L1 expression are much scarce. In this study, we confirmed that PD-L1 expression was up-regulated in ccRCC compared to paired normal tissues. Using miRDB and miRTarBase, 11 microRNAs were predicted to target PD-L1. After measuring the microRNA panel with TaqMan assays, we found that microRNA-497-5p down-regulation was associated with PD-L1 up-regulation. In TCGA-KIRC dataset, microRNA-497-5p down-regulation was also associated with PD-L1 up-regulation as well as shorter survival. We further validated that PD-L1 was a direct target of microRNA-497-5p in two RCC cell lines. In addition, microRNA-497-5p inhibited cell proliferation, clone formation and migration, while promoted apoptosis in in-vitro assays. Our study reveals a novel regulatory mechanism of PD-L1 expression and the potential of miR-497-5p as therapeutic target and biomarker deserves further investigation.

Entities:  

Keywords:  Clear cell renal cell carcinoma; PD-L1; immune checkpoint pathway; immunotherapy; microRNA-497-5p

Mesh:

Substances:

Year:  2018        PMID: 30183478     DOI: 10.1080/1061186X.2018.1479755

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  22 in total

1.  Screening of key miRNAs and evaluation of their diagnostic and prognostic values in nasopharyngeal carcinoma.

Authors:  Xianlu Zhuo; Wei Zhou; Huiping Ye; Dairong Li; Aoshuang Chang; Yongzhong Wu; Qi Zhou
Journal:  Oncol Lett       Date:  2019-04-09       Impact factor: 2.967

Review 2.  MiRNAs in renal cell carcinoma.

Authors:  Jesús Miranda-Poma; Lucía Trilla-Fuertes; Elena López-Camacho; Andrea Zapater-Moros; Rocío López-Vacas; María Isabel Lumbreras-Herrera; Ana Pertejo-Fernandez; Juan Ángel Fresno-Vara; Enrique Espinosa-Arranz; Angelo Gámez-Pozo; Álvaro Pinto-Marín
Journal:  Clin Transl Oncol       Date:  2022-06-21       Impact factor: 3.340

Review 3.  A Review of Recent Research on the Role of MicroRNAs in Renal Cancer.

Authors:  Longfei Yang; Xiaofeng Zou; Junrong Zou; Guoxi Zhang
Journal:  Med Sci Monit       Date:  2021-05-08

Review 4.  Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma.

Authors:  Antonella Argentiero; Antonio Giovanni Solimando; Markus Krebs; Patrizia Leone; Nicola Susca; Oronzo Brunetti; Vito Racanelli; Angelo Vacca; Nicola Silvestris
Journal:  J Clin Med       Date:  2020-05-24       Impact factor: 4.241

5.  HIF1α/PD-L1 axis mediates hypoxia-induced cell apoptosis and tumor progression in follicular thyroid carcinoma.

Authors:  Lingyan Zhou; Guofen Cha; Liyu Chen; Chen Yang; Dong Xu; Minghua Ge
Journal:  Onco Targets Ther       Date:  2019-08-13       Impact factor: 4.147

6.  miRNA-mRNA Associated With Survival in Endometrial Cancer.

Authors:  Xiaofeng Xu; Tao Liu; Yijin Wang; Jian Fu; Qian Yang; Jun Wu; Huaijun Zhou
Journal:  Front Genet       Date:  2019-08-20       Impact factor: 4.599

7.  Plasma Extracellular Vesicle miRNAs Can Identify Lung Cancer, Current Smoking Status, and Stable COPD.

Authors:  Hannah E O'Farrell; Rayleen V Bowman; Kwun M Fong; Ian A Yang
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 8.  Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.

Authors:  Xianjie Jiang; Jie Wang; Xiangying Deng; Fang Xiong; Junshang Ge; Bo Xiang; Xu Wu; Jian Ma; Ming Zhou; Xiaoling Li; Yong Li; Guiyuan Li; Wei Xiong; Can Guo; Zhaoyang Zeng
Journal:  Mol Cancer       Date:  2019-01-15       Impact factor: 27.401

Review 9.  The role of cancer-derived microRNAs in cancer immune escape.

Authors:  Ming Yi; Linping Xu; Ying Jiao; Suxia Luo; Anping Li; Kongming Wu
Journal:  J Hematol Oncol       Date:  2020-03-28       Impact factor: 17.388

Review 10.  Noncoding RNAs: the shot callers in tumor immune escape.

Authors:  Lei Liu; Qin Wang; Zhilin Qiu; Yujuan Kang; Jiena Liu; Shipeng Ning; Yanling Yin; Da Pang; Shouping Xu
Journal:  Signal Transduct Target Ther       Date:  2020-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.